A quadruplex tetra-primer ARMS-PCR method for the simultaneous detection of TP53 Arg72Pro, IVS3 16bp Del/Ins and IVS6+62A>G, and NQO1 C609T polymorphisms

Gene

Volumn 504, Issue 2, 2012, Pages 268-273

  Lajin, Bassam ^a   Alachkar, Amal ^a   Alhaj Sakur, Amir ^a  

^a UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

Author keywords

ARMS PCR; NQO1; P53; Polymorphism

Indexed keywords

ARGININE; NAD(P)H:QUINONE OXIDOREDUCTASE 1; OXIDOREDUCTASE; PROLINE; PROTEIN P53; UNCLASSIFIED DRUG;

AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION; APOPTOSIS; ARTICLE; DISEASE PREDISPOSITION; ETHNIC GROUP; HAPLOTYPE; HUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYRIAN ARAB REPUBLIC;

ARGININE; BASE SEQUENCE; DNA PRIMERS; GENES, P53; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROLINE; SYRIA;

TETRA;

EID: 84862773288     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.024     Document Type: Article

References (53)

1. Abravaya K., et al. Molecular beacons as diagnostic tools: technology and applications. Clin. Chem. Lab. Med. 2003, 41:468-474.
2. Anwar A., et al. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1. J. Biol. Chem. 2002, 277(16):14060-14067.
3. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(3):1188-1193.
4. Asher G., Lotem J., Kama R., Sachs L., Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(5):3099-3104.
5. Asher G., Lotem J., Sachs L., Kahana C., Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(20):13125-13130.
6. Avigad S., et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997, 14:1541-1545.
7. Belyavskaya V.A., et al. Genetic status of p53 in stomach cancer: somatic mutations and polymorphism of codon 72. Bull. Exp. Biol. Med. 2006, 141:243-246.
8. Bisof V., et al. TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur. J. Gynaecol. Oncol. 2010, 31(5):539-544.
9. Breslauer K.J., Frank R., Blocker H., Marky L.A. Predicting DNA duplex stability from the base sequence. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(11):3746-3750.
10. Costa S., et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008, 8:32.
11. di Martino E., et al. The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet. Med. 2007, 9(6):341-347.
12. Economopoulos K.P., Sergentanis T.N., Zagouri F., Zografos G.C. Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. Onkologie 2010, 33(12):666-674.
13. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003, 22:7486-7495.
14. Fisher D.E. The p53 tumor suppressor: Critical regulator of life and death in cancer. Apoptosis 2001, 6:7-15.
15. Hamajima N., Saito T., Matsuo K., Kozaki K., Takahashi T., Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn. J. Cancer Res. 2000, 91(9):865-868.
16. Hamajima N., et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int. J. Clin. Oncol. 2002, 7(2):103-108.
17. Hillebrandt S., Streffer C., Demidchik E.P., Biko J., Reiners C. Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat. Res. 1997, 381:201-207.
18. Hori H., Ohmori O., Matsumoto C., Shinkai T., Nakamura J. NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatry Res. 2003, 118(3):235-239.
19. Hu Z., et al. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 2010, 31(4):643-647.
20. Jung H.Y., et al. Association study of TP53 polymorphisms with lung cancer in a Korean population. J. Hum. Genet. 2008, 53(6):508-514.
21. Kawai S., Nishio K., Nakamura S., Sekido Y., Niwa T., Hamajima N. Multiplex PCR with confronting two-pair primers for CYP1A1 Ile462Val, GSTM1, GSTT1, and NQO1 C609T. Asian Pac. J. Cancer Prev. 2005, 6(3):346-352.
22. Kawase H., Hamajima N., Tamakoshi A., Wakai K., Saito T., Tajima K. Triplex polymerase chain reactions with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 polymorphisms: a convenient genotyping method. Asian Pac. J. Cancer Prev. 2003, 4(1):67-70.
23. Kim J.M., et al. p53 Codon 72 and 16 bp duplication polymorphisms of gastric cancer in Koreans. Korean J. Gastroenterol. 2007, 50(5):292-298.
24. Kuehl B.L., et al. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br. J. Cancer 1995, 72(3):555-561.
25. Lajin B., Alachkar A. Detection of Arg72Pro Polymorphism of the Tumor Suppressor Gene (TP53) by a Rapid One-step Tetra-primer Amplification Refractory Mutation System-PCR. Am. J. Biochem. Mol. Biol. 2011, 1(1):231-236. 10.3923/ajbmb.2011.231.236.
26. Lajin B., Alachkar A. Detection of the NQO1 C609T polymorphism by a simple one step Tri-primer Amplification Refractory Mutation System-PCR method. Am. J. Biomed. Sci. 2011, 3(2):77-83. 10.5099/aj110200077.
27. Lajin B., Alachkar A., Sakur A.A. Triplex tetra-primer ARMS-PCR method for the simultaneous detection of MTHFR c.677C>T and c.1298A>C, and MTRR c.66A>G polymorphisms of the folate-homocysteine metabolic pathway. Mol. Cell. Probes 2012, 26(1):16-20.
28. Lee J.M., Lee Y.C., Yang S.Y., Shi W.L., Lee C.J., Luh S.P. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer 2000, 89:458-464.
29. Levine A.J. P53, The cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
30. Lewis S.J., et al. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001, 34(2):177-183.
31. Lozano G., Levine A.J. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol. Carcinog. 1991, 4:3-9.
32. Malik M.A., Sharma K., Goel S., Zargar S.A., Mittal B. Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley. Oncol. Res. 2011, 19(3-4):165-169.
33. Malkin D. The role of P53 in human cancer. J. Neurooncol 2001, 51:231-243.
34. Malkinson A.M., You M. The intronic structure of cancer-related genes regulates susceptibility to cancer. Mol. Carcinog. 1994, 10:61-65.
35. Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S. Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene. EMBO J. 1984, 3:3257-3262.
36. Mavridou D., Gornall R., Campbell I.G., Eccles D.M. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br. J. Cancer 1998, 77(4):676-677.
37. Menzel H.J., et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br. J. Cancer 2004, 90(10):1989-1994.
38. Niwa Y., et al. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol. Oncol. 2005, 96(2):423-429.
39. Oefner P.J., Underhill P.A. Comparative DNA sequencing by denaturing high-performance liquid chromatography (DHPLC). Am. J. Hum. Genet. 1995, 57:A266.
40. Olivier M., et al. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther. 2009, 16:1-12.
41. Petitjean A., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
42. Pietsch E.C., Humbey O., Murphy M.E. Polymorphisms in the p53 pathway. Oncogene 2006, 25:1602-1611.
43. Shamsher M., Montano X. Analysis of intron 4 of the p53 gene in human cutaneous melanoma. Gene 1996, 176:259-262.
44. Sjalander A., Birgander R., Kivela A., Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 1995, 45(3):144-149.
45. Slatkin M., Excoffier L. Testing for linkage disequilibrium in genotypic data using the EM algorithm. Heredity 1996, 76:377e83.
46. Sun P., et al. Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in a chinese occupational population. Cancer Epidemiol. Biomarkers Prev. 2009, 18(6):1821-1828.
47. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 1999, 19:1092-1100.
48. Traver R.D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992, 52(4):797-802.
49. Wu X., et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J. Natl. Cancer Inst. 2002, 94(9):681-690.
50. Wu X., et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J. Natl. Cancer Inst. 2002, 94(9):681-690.
51. Ye S., Dhillon S., Ke X., Collins A.R., Day I.N. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001, 29(17):E88-8.
52. Ye F., Zhang J., Cheng Q., Shen J., Chen H. p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population. Cancer Lett. 2010, 287(1):117-121.
53. Yoo J., Lee Y., Kim Y., Rha S.Y. SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. BMC Bioinformatics 2008, 9:290.